SCHEMBL26375266

SCHEMBL26375266

C=C1CCC(N2C(=O)c3ccc(N4CCN(C(C)C)CC4)cc3C2=O)C(=O)N1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 17/20 0.61
▸ DDB1 Q16531 8/20 0.47
▸ ALDH1A1 P00352 2/20 0.43
▸ CHRM2 P08172 1/20 0.43
▸ OPRM1 P35372 1/20 0.43
▸ IKZF3 Q9UKT9 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ MEN1 O00255 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ HPGDS O60760 1/20 0.41
▸ IKZF1 Q13422 1/20 0.40
▸ IKZF2 Q9UKS7 1/20 0.40
▸ AR P10275 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26376778 0.89 CRBN (0.77) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL21771314 0.88 CRBN (0.65) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL21771313 0.86 CRBN (0.65) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL27099517 0.86 CRBN (0.65) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL27099506 0.85 CRBN (0.61) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL27099498 0.84 CRBN (0.59) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL27099503 0.83 CRBN (0.61) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL27099504 0.83 CRBN (0.61) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL26500883 0.83 CRBN (0.47) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL26375243 0.83 CRBN (0.47) CRBNIKZF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025863-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2024-01-25 — — US disclosed
US-20230321253-A1 BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-10-12 — — US disclosed
US-20230293702-A1 QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293702-A1 QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS RAB1A, SOS1, IQGAP1 CRBN 3656/4885DDB1 2095/4885ALDH1A1 2378/4885
US-20240025863-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS SOS1, SOS2, SOST CRBN 474/4885DDB1 985/4885ALDH1A1 3542/4885
US-20230321253-A1 BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF KRAS, MDM2, NRAS CRBN 252/4885DDB1 510/4885ALDH1A1 3243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback